Objective: To observe the clinical effects of different courses of HBV Negative Conversion Powder in the treatment of patients with Hepatitis B virus (HBV)-related liver cirrhosis via treatment with nucleotide analogues, as so to provide guidance for standardized use of this drug.Methods: A total of 172 patients with HBV-related liver cirrhosis who showed HBV DNA negative conversion via treatment with nucleotide analogues were enrolled and randomly divided into four groups (groups A, B, C and D, 43 cases in each group). Patients in four groups were treated with original nucleotide analogues, based on which, group A was added with HBV Negative Conversion Powder for 12 months, group B with HBV Negative Conversion Powder for 9 months, group C with HBV Negative Conversion Powder for 6 months, but group D without HBV Negative Conversion Powder. The total courses of treatment were 12 months for all groups.Results: The liver function, four indexes of liver fibrosis, the condition of abdominal ultrasonogram and liver stiffness in groups A, B and C were significantly improved when compared with group D treated with original nucleoside analog alone (P